# Many NC Candidates Support Medical Marijuana Legalization | Raleigh News & Observer > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/north-carolina-medical-cannabis-program-support/ > **Published:** 2026-02-27T15:01:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:13:29-04:00 > **Clinical Summary:** Explore the growing support for the North Carolina medical cannabis program and its potential impact on patient access and regulation. --- ✦ New CED Clinical Relevance#55Clinical ContextBackground information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyPainCancerNeurology Why This MattersAs North Carolina moves toward potential medical marijuana legalization, clinicians need to recognize that patients with [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), cancer, and epilepsy currently lack legal access to [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) that demonstrate efficacy in peer-reviewed literature, forcing them to either forgo treatment or turn to unregulated sources with unknown potency and contaminant profiles. Regulated medical cannabis programs would enable healthcare providers to counsel patients on evidence-based dosing, drug interactions, and monitoring while ensuring product safety and consistency through standardized testing. This shift from prohibition to clinical oversight would allow systematic collection of safety and efficacy data within your patient population while reducing liability exposure from patients self-managing cannabis without professional guidance. Clinical Summary This article reports on political momentum in North Carolina toward medical [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) rather than presenting [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) data. The piece notes that multiple legislative attempts with bipartisan support have sought to establish a regulated medical cannabis program for patients with [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), cancer, epilepsy, and other qualifying conditions, though North Carolina currently lacks legal patient access. The summary indicates that candidate support for legalization reflects shifting public opinion favoring patient access to regulated cannabis therapies. However, the article does not present randomized controlled trials, systematic reviews, or clinical outcome data comparing cannabis efficacy to standard treatments for the mentioned conditions. From a clinical perspective, legalization could facilitate better documentation of cannabis use in patient records and enable more rigorous clinical observation of therapeutic and adverse effects in a regulated framework. Physicians in North Carolina should remain informed of evolving legislative developments, as medical [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) could create new clinical assessment responsibilities regarding patient candidacy and monitoring for conditions where evidence of benefit exists. Dr. Caplan’s Take“What we’re seeing in North Carolina is a legitimate clinical gap where patients with intractable pain, chemotherapy-induced nausea, and treatment-resistant epilepsy have evidence-based cannabis options available in regulated markets elsewhere, yet remain forced into either suffering or legal jeopardy at home. A regulated medical program doesn’t solve everything, but it does shift us from ideology-based prohibition to evidence-based prescribing, which is where medicine should operate.” Clinical Perspective While political support for medical marijuana legalization in North Carolina reflects growing recognition that cannabis may benefit patients with conditions like chronic pain, cancer, and epilepsy, clinicians should recognize that the evidence base remains heterogeneous and evolving, with variable quality across available studies and limited long-term safety data in many populations. The shift from unregulated to regulated access could improve product standardization and reduce contamination risks, but providers must acknowledge that legalization does not automatically resolve questions about optimal dosing, drug interactions, or suitability for individual patients. Importantly, regulatory approval at the state level does not imply FDA endorsement, and cannabis remains a Schedule I substance federally, creating ongoing legal and documentation uncertainties for prescribers. As a practical matter, clinicians in states moving toward medical marijuana programs should begin familiarizing themselves with the pharmacology and potential adverse effects of cannabinoids so that they can engage in informed shared decision-making 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Many+NC+candidates+support+medical+marijuana+legalization+%7C+Raleigh+News+%26amp%3B+Observer+%40drcaplan&url=https%3A%2F%2Fnewsobserver.com%2Fnews%2Fpolitics-government%2Felection%2Farticle314857258.html)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fnewsobserver.com%2Fnews%2Fpolitics-government%2Felection%2Farticle314857258.html)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Many+NC+candidates+support+medical+marijuana+legalization+%7C+Raleigh+News+%26amp%3B+Observer+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fnewsobserver.com%2Fnews%2Fpolitics-government%2Felection%2Farticle314857258.html)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Top of the Feed: Policy Momentum, Patient Safety, and the Science Still Catching Up – February 25, 2026](https://cedclinic.com/medical-cannabis-program-patient-registration-access-2026/) 📰 Source: [https://newsobserver.com/news/politics-government/election/article314857258.html](https://newsobserver.com/news/politics-government/election/article314857258.html) Further Reading Evidence Watch[The Brain Science Behind the Munchies – Nautilus Magazine](https://cedclinic.com/cannabis-appetite-stimulation-neuroscience/) Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DOH sets conditions on proposed medical cannabis legalization | Philippine News Agency](https://cedclinic.com/philippine-medical-cannabis-legalization-conditions/) Learn about the Department of Health's conditions on medical cannabis legalization efforts in the Philippines. [Read More](https://cedclinic.com/philippine-medical-cannabis-legalization-conditions/) [North Carolina Advisory Group Recommends Legalizing, Regulating THC Products](https://cedclinic.com/north-carolina-cannabis-regulation-legalizing-thc-products/) Details on the advisory group's recommendations for legalizing and regulating THC products in North Carolina. [Learn More](https://cedclinic.com/north-carolina-cannabis-regulation-legalizing-thc-products/) [North Carolina advisory group recommends legalizing marijuana for adults – WXII](https://cedclinic.com/north-carolina-cannabis-legalization-advisory/) Coverage of North Carolina's advisory group's push for adult marijuana legalization. [Explore Article](https://cedclinic.com/north-carolina-cannabis-legalization-advisory/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).